Mosaic ImmunoEngineering (OTCMKTS:CPMV) Releases Quarterly Earnings Results

Mosaic ImmunoEngineering (OTCMKTS:CPMV) announced its quarterly earnings results on Tuesday. The company reported ($0.03) earnings per share (EPS) for the quarter, Zacks reports.

Mosaic ImmunoEngineering Stock Performance

OTCMKTS:CPMV opened at $0.54 on Wednesday. The company has a market cap of $3.91 million, a PE ratio of -3.60 and a beta of 0.11. Mosaic ImmunoEngineering has a 52-week low of $0.10 and a 52-week high of $1.13. The stock has a 50-day simple moving average of $0.70 and a 200 day simple moving average of $0.84.

About Mosaic ImmunoEngineering

Mosaic ImmunoEngineering, Inc, a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals.